OCT 30, 2014 10:30 AM PDT

Therapeutic Drug Monitoring (TDM) in Cancer Chemotherapy: A Tool for Optimizing Drug Management

Speaker
  • Associate Professor of Pathology, Clinical Toxicology, Director, Point-of-Care Testing, Johns Hopkins University School of Medicine
    Biography
      Dr. William Clarke is an associate professor of pathology at the Johns Hopkins University School of Medicine. His research focuses on the development of analytical methods for drug analysis, clinical mass spectrometry, and devices for point-of-care testing. Dr. Clarke serves as the director of Clinical Toxicology as well as Critical and Point-of-Care Testing Program at The Johns Hopkins Hospital.

      His team's current projects include qualitative screening for antiretroviral drugs and substances of abuse in various HIV- prevention clinical trials, development and validation of mass spectrometry methods for clinical analysis, and development of clinical assays for use on microfluidic platforms.

      Dr. Clarke received his B.S. in Chemistry from the University of Nebraska at Kearney and his Ph.D. in Analytical Chemistry from the University of Nebraska-Lincoln, as well as an M.B.A. from the Carey School of Business at Johns Hopkins University. He completed a post-doctoral fellowship in Clinical Chemistry at the Johns Hopkins School of Medicine.

    Abstract

    Many drugs currently used for anti-cancer therapy demonstrate significant inter-individual variability that cannot be normalized using body weight or body surface area. There is an increasing amount of evidence in the scientific literature describing the use of therapeutic drug monitoring (TDM) to inform dosing of these drugs can lead to more effective treatment. This presentation will discuss the scientific literature addressing inter-individual variability of these drugs, the concept of maximum tolerated dose (MTD), and why an approach using maximum tolerated exposure (MTE) might be a better way to manage some chemotherapeutic drugs. Specific examples of TDM in oncology will be discussed including 5-fluorouracil, taxanes, and tyrosine kinase inhibitors.


    Show Resources
    You May Also Like
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    FEB 19, 2020 11:00 AM PST
    C.E. CREDITS
    FEB 19, 2020 11:00 AM PST
    DATE: February 19, 2020TIME: 11:00am PST, 2:00pm EST...
    FEB 26, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 26, 2020 9:00 AM PST
    DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
    DEC 05, 2019 9:00 AM PST
    C.E. CREDITS
    DEC 05, 2019 9:00 AM PST
    DATE: December 5, 2019TIME: 9:00am PST, 12:00pm EST Characterization of the spatial distribution and abundance of proteins and mRNAs with morphological context within tissues e...
    MAY 08, 2020 10:00 AM PDT
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    Loading Comments...
    Show Resources